Navigation Links
RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks
Date:1/17/2011

STANFORD, Calif. Researchers at the Stanford University School of Medicine, in collaboration with BioParadox, Inc., have published data supporting the use of platelet-rich plasma as a promising biologic treatment for myocardial infarction (heart attack).

The findings were published online in Cardiovascular Revascularization Medicine and will be presented at The Sixth International Conference on Cell Therapy for Cardiovascular Disease at Columbia University Medical Center, New York City, on January 20, 2011.

Platelet-rich plasma (PRP) has been identified as a novel biologic treatment for wound healing and sports-related injuries. Studies indicate PRP stimulates cell repair via growth factor release and by attracting reparative cells. Only recently, however, have scientists begun to study PRP's potential in repairing damaged cardiovascular tissue.

Working with colleagues at Stanford University Medical Center, lead author Allan Mishra, MD, a leading PRP researcher, studied the effects of RevaTen PRP (a proprietary formulation of concentrated platelets and white blood cells) on cardiac function after inducing cardiac ischemia (damage to myocardial tissue caused by blood restriction) in mice. The research was conducted under the direction of Robert Robbins, MD, chairman of the department of cardiothoracic surgery at Stanford University.

In this study of 28 mice, researchers induced ischemia by either permanently occluding the left anterior descending artery (Group A) or temporarily ligating it for 45 minutes (Group B). The hearts were then injected with RevaTen PRP or saline control. In order to assess cardiac function after treatment, magnetic resonance images were taken at seven days post-procedure (Group A) and 21 days (Group B). Tissue from all hearts was collected for histopathologic evaluation.

In both groups, mice that received PRP after ischemia had significantly better cardiac function as meas
'/>"/>

Contact: Patti Davis
patti@davismedpr.com
630-920-8042
DAVIS MEDPR, Inc.
Source:Eurekalert

Page: 1 2

Related biology news :

1. How Toxoplasma gondii gets noticed
2. Plasma produces KO cocktail for MRSA
3. Modeling Toxoplasma focus of workshop
4. Toxoplasma gondii spreads in the habitat of the Iberian lynx
5. Atmospheric pressure plasma jet from a grounded electrode
6. Grant advances quark-gluon plasma studies

7. Scripps Research scientists redefine the role of plasma cells in the immune system
8. MIT researchers study the danger of toxoplasma parasites
9. Long-term study shows effect of climate change on animal diversity
10. New approach to treating cystic fibrosis lung infection shows promise
11. Research shows Brazilian acai berry antioxidants absorbed by human body
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... As climate change shifts the geographic ranges in which ... it has on their parasites. Does an increased range ... as well? , Not necessarily, says a team of ... Armand Kuris. In a study published in the ... that for some species, the opposite may happen: Hosts ...
(Date:7/9/2014)... Emerging fungal pathogens pose a greater threat ... population declines of amphibians, bats, corals, bees and ... Florida published in the prestigious journal Nature ... immunological resistance to a deadly chytrid fungus implicated ... resistance is important because it is the basis ...
(Date:7/9/2014)... with traumatic injuries have identified an immune marker ... a hospital-acquired infection. The study, led by clinician-scientists ... June in the journal Shock , is ... to the clinical implementation of quick-turnaround immune function ... system damage following critical illness or injury in ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4USF study: Amphibians can acquire resistance to deadly fungus 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... biologists is figuring out which among the hundreds of genetic ... driving the cancer,s spread. Using a new technique ... that appears to drive progression of small cell lung cancer, ... percent of lung cancer cases. The gene, which ...
... Foundation has awarded Delft University of Technology (TU Delft, the ... project is to develop new technology for processing human waste ... costs affordable to the poor in developing countries. ... at the AfricaSan conference in Rwanda (www.africasan3.com) as part of ...
... Knowing how trees grow and how they age may ... warmer climate, for instance, and other changes. Little is known, ... tree growth. "Although much research has been done on how ... increase in size," says research ecologist Frederick (Rick) Meinzer, "structure ...
Cached Biology News:New lung-cancer gene found 2Reinventing the toilet for safe and affordable sanitation 2
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... target drug delivery. , ... Cary, NC (PRWEB) October ... company ) and Auburn University announced today a joint research project ... Veterinary Medicine,s Department of Pathobiology, the six-month study is under the ...
... 2008 5:00 p.m. EST, HOPKINTON, Mass., Oct. ... ) will conduct a conference call discussing the,company,s ... EST on Monday,November 10. Kevin Hrusovsky, President and ... will host the call. Management will,discuss operational and ...
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ), a clinical-stage ... novel medicines in the areas of,hepatitis C and ... the third quarter ended September 30, 2008., ... of our hepatitis C,development programs," said Steve Worland ...
Cached Biology Technology:Calvert Research and Auburn University Announce Joint Venture 2Calvert Research and Auburn University Announce Joint Venture 3Caliper Life Sciences' Third Quarter 2008 Financial Results Conference Call Notice 2Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 2Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 3Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 4Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 5Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 6Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 7Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 8
...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... The NEW HandyStep electronic from BRAND ... pipetting. It is the only electronic, ... standard syringe tips, including BRAND PD-Tip ... Plus, Fisherbrand Dispenser Tips,and VWRbrand Combi-Syringes. ...
Biology Products: